MDNAF Medicenna Therapeutics Corp. IFRS
Pharmaceutical Preparations · OTC · SEC CIK 1807983 · Reporting currency CAD · Fiscal year ends 03/31
Financial factors as of 2023-03-31 (FY2023), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Unit: CAD | FY2023*2023-03-31 | FY2022*2022-03-31 |
|---|---|---|
| Income statement | ||
| Revenue | — | — |
| R&D expense | 9.30M | 14.72M |
| SG&A expense | 7.00M | 7.76M |
| Pretax income | -10.05M | -22.58M |
| Income tax | 0 | 0 |
| Net income | -10.05M | -22.58M |
| EPS (basic) | -0.16 | -0.42 |
| EPS (diluted) | — | — |
| Balance sheet | ||
| Cash & equivalents | 33.60M | 20.54M |
| Current assets | 36.38M | 23.39M |
| Intangibles | 61,000 | 65,000 |
| Total assets | 36.45M | 23.46M |
| Current liabilities | 3.80M | 2.62M |
| Total liabilities | 6.96M | 2.62M |
| Shareholders' equity | 29.49M | 20.84M |
| Shares outstanding | 69.64M | 55.65M |
| Cash flow statement | ||
| Operating cash flow | — | -23.58M |
| Investing cash flow | — | 10.05M |
| Financing cash flow | — | 3.88M |
| Stock-based compensation | — | 1.42M |
Free plan shows the latest 2 periods; Pro shows all 4 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· This company does not report gross profit in XBRL.
· This company reports EPS only by share class (e.g. class A/B), so it is shown as —.
· Amounts are in the company's reporting currency, CAD, not USD; the site does no currency conversion.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.